• Prescribing Information
  • Medical Information
  • Patient Site
  • Order Prevnar 20TM
  • Pneumococcal pneumonia can be serious and may lead to hospitalization1-3

    Patients can be hospitalized for pneumococcal pneumonia at any time of year4*​​​​​​​​​​​​​​​​​​​​​​​​​​​​

    The mean length of stay is ~5 days for adults aged 18 and older requiring hospitalization3†


    ​​​​​​​Rates of pneumococcal pneumonia requiring hospitalization, by age and risk profiles, 2013–2015​​​​​​​5‡

    Older age and the presence of certain comorbid conditions can increase the risk of pneumococcal pneumonia in adults. The risk further multiplies with each additional comorbid condition, compared to healthy adults of same age.​​​​​​​5,6


    *Based on an active population-based surveillance study of adults (N=2488) aged 18 or older with CAP requiring hospitalization.4

    ​​​​​​​Based on Agency for Healthcare Research and Quality-reported outcomes by patient and hospital characteristics for various principal diagnoses, 2017.3

    ​​​​​​Adults with chronic conditions include those who were immunocompetent with 1 or more chronic medical conditions. Healthy adults included those without evidence of any high-risk or at-risk condition.5

    ​​​​​​§Chronic conditions included: alcoholism, asthma, chronic cardiovascular disease, chronic liver disease, chronic pulmonary disease, diabetes, and smoking.5

    ||Immunocompromising conditions included: functional/anatomical asplenia, HIV, chronic renal failure, nephrotic syndrome, immunosuppressants, malignant neoplasm, solid organ transplant, chronic oral steroid use, congenital immunodeficiency, and disease of white blood cells.5


    References: 1. Ramirez JA, Wiemken TL, Peyrani P,  et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65:1806-1812. 2. National Foundation for Infectious Diseases. Understanding pneumococcal disease. Accessed November 25, 2020. https://www.nfid.org/wp-content/uploads/2019/09/5-Pneumococcal-Disease-Backgrounder.pdf  3. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD.  Accessed November 25, 2020. http://hcupnet.ahrq.gov/  4. Jain S, Self WH, Wunderink RG, et al; for the CDC EPID Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427. 5. Pelton SI, Bornheimer R, Doroff R, Shea KM, Sato R, Weycker D. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68:1831-1838. 6. Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. Rethinking risk for pneumococcal disease in adults: the role of risk stacking. Open Forum Infect Dis. 2015;2:ofvo20. 7. Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2021. 8. Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019. 9. Poehling K, Kobayashi M for the Pneumococcal Work Group. Introduction of the Pneumococcal Work Group. Presented at: Advisory Committee on Immunization Practices; October 28, 2020. Accessed February 5, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/pneumo-01-Poehling-Kobayashi-508.pdf  10. Grant LR, Ramirez J, Self WH, et al. Streptococcus pneumoniae Serotype Distribution and Coverage of Pneumococcal Conjugate Vaccines in Adults Hospitalized with Community-Acquired Pneumonia in the United States. ISPPD. 2020; abstract #879. Accessed February 5, 2021. https://cslide.ctimeetingtech.com/isppd20/attendee/confcal/presentation/list?q=grant
    ​​​​​

    Additional serotype protection

    Help protect your patients from more of the disease that can threaten their health with the most coverage from a pneumococcal conjugate vaccine.7-10

    See the coverage difference

    ** This is an optional area where footnotes can live.

    Studied across adult populations

    Prevnar 20™ demonstrated immunogenicity in pneumococcal vaccine-naïve and previously vaccinated adults.​​​​​​​1

    Evaluate the studies

    ** This is an optional area where footnotes can live.

    This site is intended only for US residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    © 2021 Pfizer Inc.

    ​​​​​​​​​​​​All rights reserved.

    Marketed by Pfizer Inc.
    November 2021

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    Marketed by Pfizer Inc.
    © 2021 Pfizer Inc. ​​​​​All rights reserved. November 2021

    Indication

    • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
    • This indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      ​​​​​​​
      • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™, Prevnar 13®, or to diphtheria toxoid is a contraindication
      • Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™
      • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
      • For Prevnar 20™, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age 
      • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash 

      Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

      Please click for Prevnar 20™ Full Prescribing Information.

      Please click for Prevnar 13® Full Prescribing Information.


      • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older 
      • The indication of Prevnar 20™ for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

      Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine